…
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells. It also engages in the development of CYAD-01, a CAR T-cell product candidate based on the natural killer group 2D (NKG2D); CYAD-02, an autologous NKG2D-based CAR T-cell candidate used to target the NKG2D ligands (NKG2DL) MICA/B to prevent cell fratricide and improve cell persistence; and CYAD-211, an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell candidate. In addition, the company offers C-Cathez, an intra-myocardial injection catheter. It has a license agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; research and development collaboration, and license agreements with Hr for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells; and a license agreement with Mesoblast to develop and commercialize C-Cathez. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Celyad Oncology SA is a clinical-stage biopharmaceutical company developing cell-based immunotherapies, principally CAR-T approaches, for oncology indications. Its long-term growth drivers include progress in clinical trials, potential regulatory approvals, and advancement of scalable manufacturing and platform technologies that may support commercialization, and investors may find the company attractive for upside linked to successful clinical outcomes and platform validation.
Material investment risks include clinical and regulatory setbacks, lack of commercial revenue and recurring financing needs that could dilute shareholders, intense competition in cell therapy, and significant manufacturing and operational complexity.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -0.66M | -5.96M | -8.51M | -40.87M | -26.50M |
| Net income | 0.83M | -5.82M | -8.45M | -40.94M | -26.51M |
| Selling general administrative | 1.70M | - | 5.71M | 10.34M | 9.66M |
| Selling and marketing expenses | - | - | 0.21M | 0.24M | 0.43M |
| Gross profit | 1.93M | 0.92M | 0.03M | -1.44M | -1.52M |
| Reconciled depreciation | 0.17M | - | - | 1.44M | 1.52M |
| Ebit | -7.18M | -5.84M | -8.56M | -41.13M | -26.93M |
| Ebitda | -7.01M | -5.39M | -7.76M | -39.70M | -25.41M |
| Depreciation and amortization | 0.17M | 0.45M | 0.79M | 1.44M | 1.52M |
| Operating income | -7.18M | -6.26M | -8.46M | -40.86M | -26.39M |
| Other operating expenses | 7.20M | 6.45M | 8.56M | 20.26M | 26.91M |
| Interest expense | 0.06M | 0.12M | 0.08M | 0.20M | 0.26M |
| Tax provision | 0.00M | - | - | 0.07M | 0.01M |
| Interest income | 0.01M | - | - | 0.01M | 0.03M |
| Net interest income | -0.05M | - | - | -0.18M | -0.12M |
| Income tax expense | -1.49M | -0.14M | -0.19M | 0.07M | 0.01M |
| Total revenue | 0.02M | 0.19M | 0.10M | 0.00M | 0.00M |
| Total operating expenses | 9.11M | 7.18M | 8.49M | 20.26M | 26.91M |
| Cost of revenue | -1.91M | -0.73M | 0.07M | 1.44M | 1.52M |
| Total other income expense net | 6.53M | 0.30M | -0.05M | -0.01M | -0.11M |
| Net income from continuing ops | 0.83M | - | - | -40.94M | -26.51M |
| Net income applicable to common shares | - | - | - | -40.94M | -26.51M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 4.30M | 9.93M | 16.28M | 19.72M | 79.94M |
| Intangible assets | 0.02M | 0.41M | 0.05M | 0.86M | 35.28M |
| Other current assets | 1.00M | 0.99M | 3.74M | 0.45M | 0.25M |
| Total liab | 1.86M | 26.05M | 9.98M | 15.40M | 36.30M |
| Total stockholder equity | 2.44M | -16.12M | 6.30M | 4.32M | 43.64M |
| Deferred long term liab | - | - | - | 0.41M | 0.47M |
| Other current liab | 0.66M | 0.69M | 1.53M | 4.21M | 4.86M |
| Common stock | 9.22M | 8.22M | 32.95M | 78.58M | 78.58M |
| Capital stock | 9.22M | - | - | 78.58M | 78.58M |
| Retained earnings | -363.37M | -364.20M | -358.37M | -349.95M | -309.00M |
| Other liab | - | - | - | 4.86M | 20.75M |
| Good will | 0.00M | - | 0.34M | 0.00M | 0.88M |
| Other assets | - | - | - | 4.13M | 6.71M |
| Cash | 1.71M | 4.20M | 7.00M | 12.45M | 30.02M |
| Total current liabilities | 1.82M | 2.85M | 2.93M | 10.43M | 13.83M |
| Current deferred revenue | 0.65M | 0.79M | 0.51M | 1.33M | 1.46M |
| Net debt | -1.71M | 13.34M | -5.95M | -12.19M | -27.39M |
| Short term debt | - | 0.14M | 0.16M | 0.14M | 0.90M |
| Short long term debt total | - | 17.54M | 1.06M | 0.26M | 2.63M |
| Other stockholder equity | - | 0.00M | 0.00M | 6.32M | 6.32M |
| Property plant equipment | - | - | - | 0.31M | 3.25M |
| Total current assets | 3.50M | 6.51M | 11.12M | 14.82M | 34.29M |
| Net tangible assets | - | - | - | 3.86M | 7.95M |
| Short term investments | - | - | - | 0.00M | 0.00M |
| Net receivables | 0.79M | 0.91M | 0.38M | 1.26M | 2.34M |
| Inventory | 0.00M | 0.42M | -0.08M | - | - |
| Accounts payable | 0.51M | 1.23M | 1.24M | 4.75M | 6.61M |
| Accumulated other comprehensive income | 356.59M | 339.86M | 331.73M | 269.36M | 267.73M |
| Non currrent assets other | 0.03M | 0.10M | 2.94M | 3.72M | 6.24M |
| Non current assets total | 0.80M | 3.41M | 5.16M | 4.89M | 45.65M |
| Capital lease obligations | 0.00M | - | - | 0.26M | 2.63M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | - | - | 7.20M | -0.13M |
| Change to liabilities | - | - | - | -4.32M | 2.96M |
| Total cashflows from investing activities | 3.01M | - | - | 7.20M | -0.13M |
| Net borrowings | - | - | - | -0.90M | -1.14M |
| Total cash from financing activities | 1.39M | 2.98M | 9.36M | 3.24M | 39.52M |
| Change to operating activities | - | - | - | -4.01M | 1.41M |
| Net income | 0.83M | -5.82M | -8.45M | -40.94M | -26.51M |
| Change in cash | -2.49M | - | -5.44M | -17.57M | 12.78M |
| Begin period cash flow | 4.20M | 7.00M | 12.45M | 30.02M | 17.23M |
| End period cash flow | 1.71M | 4.20M | 7.00M | 12.45M | 30.02M |
| Total cash from operating activities | -6.90M | -5.68M | -15.20M | -28.01M | -26.64M |
| Issuance of capital stock | 0.96M | - | - | - | 36.57M |
| Depreciation | 0.17M | 0.45M | 0.79M | 1.44M | 1.52M |
| Other cashflows from investing activities | - | - | 1.34M | 0.23M | 0.27M |
| Change to inventory | 0.07M | -0.42M | - | -0.31M | - |
| Change to account receivables | - | - | -1.21M | 0.31M | -1.56M |
| Sale purchase of stock | - | - | - | -0.12M | - |
| Other cashflows from financing activities | 0.43M | 2.98M | 9.50M | 4.14M | 40.66M |
| Change to netincome | - | - | - | 15.50M | -3.06M |
| Capital expenditures | 0.00M | 0.12M | 0.90M | 0.12M | 0.39M |
| Change in working capital | -1.47M | -0.18M | -1.21M | -4.01M | 1.41M |
| Stock based compensation | 0.12M | - | 0.94M | 1.62M | 2.17M |
| Other non cash items | -6.43M | -0.13M | -7.28M | 13.88M | -4.70M |
| Free cash flow | -6.90M | -5.68M | -16.10M | -28.13M | -27.04M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CLYYF Celyad Oncology SA |
- -% |
0.28 | 17.50 | - | 790.54 | 5.46 | 609.28 | 12.00 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells. It also engages in the development of CYAD-01, a CAR T-cell product candidate based on the natural killer group 2D (NKG2D); CYAD-02, an autologous NKG2D-based CAR T-cell candidate used to target the NKG2D ligands (NKG2DL) MICA/B to prevent cell fratricide and improve cell persistence; and CYAD-211, an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell candidate. In addition, the company offers C-Cathez, an intra-myocardial injection catheter. It has a license agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; research and development collaboration, and license agreements with Hr for the use of shRNA to downregulate such targets in immune cells and the combination of shRNAs with a chimeric antigen receptor in immune cells; and a license agreement with Mesoblast to develop and commercialize C-Cathez. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
| Name | Title | Year Born |
|---|---|---|
| Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BME | Co-Founder, CFO, Interim CEO & Director | 1956 |
| Mr. David Georges | VP of Fin. & Admin. | NA |
| Sara Zelkovic | Communications & Investor Relations Director | NA |
| Mr. Philippe Nobels | Chief HR Officer & VP of HR | 1966 |
| Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D. | Chief Medical Officer | 1965 |
| Ms. An Phan | Head of Legal | NA |
| Mr. Hannes Iserentant | Head of Intellectual Property | NA |
| Dr. Frédéric Lehmann | VP of Clinical Devel. & Medical Affairs | 1964 |
| Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BME | Co-Founder & Executive Director | 1956 |
| Mr. Matthew R. Kane | Chief Executive Officer | 1977 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.